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Summary Beta-blocker therapy has a mortality benefit in patients with hypertension,
heart failure and coronary artery disease, as well as during the perioperative period.
These drugs have traditionally been considered contraindicated in patients with
chronic obstructive pulmonary disease (COPD). The objective of this study was to
assess the effect of cardioselective beta-blockers on respiratory function of patients
with COPD. Comprehensive searches were performed of the EMBASE, MEDLINE and
CINAHL databases from 1966 to May 2001, and identified articles and related reviews
were scanned. Randomised, blinded, controlled trials that studied the effects of
cardioselective beta-blockers on the forced expiratory volume in 1 s (FEV1) or
symptoms in patients with COPD were included in the analysis. Interventions studied
were the administration of beta-blocker, given either as a single dose or for longer
duration, and the use of beta2-agonist given after the study drug. Outcomes
measured were the change in FEV1 from baseline and the number of patients with
respiratory symptoms. Eleven studies of single-dose treatment and 8 of continued
treatment were included. Cardioselective beta-blockers produced no significant
change in FEV1 or respiratory symptoms compared to placebo, given as a single dose
(2.05% [95% CI, 6.05% to 1.96%]) or for longer duration (2.55% [CI, 5.94% to
0.84]), and did not significantly affect the FEV1 treatment response to beta2-
agonists. Subgroup analyses revealed no significant change in results for those
participants with severe chronic airways obstruction or for those with a reversible
obstructive component. In conclusion, cardioselective beta-blockers given to patients
with COPD do not produce a significant reduction in airway function or increase the
incidence of COPD exacerbations. Given their demonstrated benefit in conditions
such as heart failure, coronary artery disease and hypertension, cardioselective beta-
blockers should be considered for patients with COPD.








Beta-adrenergic blocking agents, or beta-blockers,
are indicated in the management of angina
pectoris, myocardial infarction, hypertension, con-
gestive heart failure, cardiac arrhythmia and
thyrotoxicosis, as well as to reduce complications
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in the perioperative period.1–14 Despite clear
evidence of their effectiveness and mortality
benefit, clinicians are often hesitant to administer
them in the presence of a variety of common
conditions for fear of adverse reactions.15–18 Many
patients with chronic obstructive pulmonary dis-
ease (COPD) have concomitant conditions such as
angina or cardiac arrhythmias necessitating the use
of beta-blockers. However, review articles and
practice guidelines usually list asthma and COPD
as contraindications to beta-blocker use, citing
cases of acute bronchospasm occurring during non-
cardioselective beta-blocker use.6,8,19–23 Cardiose-
lective beta-blockers, or beta1-blockers, have over
20 times more affinity for beta1 receptors as for
beta2 receptors, and theoretically should have
significantly less risk for bronchoconstriction.24
A recent meta-analysis demonstrated that beta1-
blockers, given to patients with mild to moderate
reversible airway disease, do not produce clinically
significant adverse respiratory effects.25 The study
was not designed to make recommendations about
people with significant chronic airway obstruction
because only a few COPD patients met the
reversibility criteria for the study. Patients with
COPD are at greater risk of ischemic heart disease
than asthmatics, so would benefit from the use of
beta-blockers. However, they also have more
severe airways obstruction, so may be more
sensitive to small changes in FEV1 due to beta-
blockade.
The objective of this review was to evaluate the
effect of cardioselective beta1-blockers on respira-
tory function in patients with COPD, as assessed by
forced expiratory volume in 1 s (FEV1) and the
incidence of symptoms. Another objective was to
evaluate the FEV1 response to beta2-agonists for
those patients treated with beta1-blockers as
compared to placebo. This analysis has already




A search was performed to identify all relevant
published clinical trials that address the effects of
cardioselective beta-blockers on airway function in
patients with COPD. A comprehensive search of
EMBASE, MEDLINE and CINAHL was performed to
identify all relevant human clinical trials published
between 1966 and May 2001. Terms used in the
search were asthma*, bronchial hyperreactivity*,
respiratory sounds*, wheez*, obstructive lung dis-
ease*, or obstructive airway disease*, and adrener-
gic antagonist*, sympatholytic* or adrenergic
receptor block*. Trials were not excluded on the
basis of language. The search was further augmen-
ted by scanning references of identified articles or
reviews, and of abstracts at clinical symposia.
Study selection
Two investigators independently evaluated studies
for inclusion and the observed percentage agree-
ment between raters was calculated. Trials were
included if they: (1) reported FEV1 measured at
rest, either as litres or as a percent of the normal
predicted value at baseline and follow-up, or
reported symptoms for study drug and placebo,
(2) were randomised, controlled, and single or
double-blinded, and (3) included only subjects with
COPD, demonstrated by a baseline FEV1 of o80%
normal predicted value, or as defined by the
guidelines of the American Thoracic Society.27
Cross-over trials were considered to be randomised
if different interventions were administered in
random order. Controlled trials were those with
placebo or comparative controls.
The decision was made to evaluate only beta1-
blockers in this study as these are the ones most
frequently used in clinical practice. Studies were
included only if participants had documented
COPD, in order to evaluate the effect of beta1-
blockers in patients with chronic airway obstruc-
tion. Participants were not included or excluded on
the basis of reversibility of their airway obstruc-
tion. Only blinded studies were included in order to
decrease the risk of reporting bias that is inherent
in unblinded studies. It was decided, a priori, that
comparative trials studying FEV1 treatment effects
of beta1-blockers without placebo controls would
be included as long as they compared various
interventions in a blinded randomised manner.
The results of the trials without placebo controls
were evaluated separately. For studies that eval-
uated symptoms, only those that have placebo
controls for comparison to active treatment were
included.
Assessment of validity
The methodological quality of each trial was
assessed, using the following factors. (1) Was
the study randomised? If so, was the randomisa-
tion procedure adequate? (2) Was the trial
placebo-controlled? (3) Were the patients and
people administering the treatment blind to the
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intervention? (4) Were withdrawals and drop-outs
described?
Study characteristics
The main intervention studied was the use of
intravenous or oral beta1-blockers versus placebo
or other interventions, given either as a single dose
or for an extended period. A second intervention
studied was the administration of a beta2-agonist,
either intravenously or by inhalation, given after
the study medication or placebo. For single-dose
trials the beta2-agonist was given 1 h after the
administration of an intravenous agent, and 3–6 h
after an oral agent was given.
Data extraction
Two independent reviewers extracted data from
the selected articles, reconciling differences by
consensus. Outcomes measured were: (1) the
change in FEV1 from baseline in response to study
group or placebo, (2) FEV1 response to beta2-
agonist administered after placebo or study drug,
and (3) reported symptoms during the trial, such as
wheezing, dyspnea, COPD exacerbation or hospita-
lisation, for study drug or placebo.
Respiratory symptoms were measured according
to a self-reporting system used for each trial, and
were reported as the number of patients with
symptoms. For single-dose trials respiratory symp-
toms were described as wheezing, dyspnea or
breathlessness. For trials of longer duration pa-
tients were to record symptoms such as acute
shortness of breath, increased respiratory symp-
toms, asthma attacks or COPD exacerbations.
Data synthesis
To estimate the net treatment effect, the ratio of
the lowest measured FEV1 value seen after study
drug to baseline FEV1 were measured for both
placebo and active treatment, and recorded as the
percent change from baseline. The treatment
response was then compared to the placebo
response. For those studies without placebo con-
trols the treatment response for each intervention
was measured and the placebo response was
estimated from the available placebo-controlled
trials. The results from these trials are reported
separately.
For those trials that did not provide information
on the standard deviation (SD) for the study results,
the average SD was obtained from trials that
provided such data, calculated separately for
placebo and treatment responses. This pooled SD
was used for all trials that did not provide SD data.
A sensitivity analysis was performed to evaluate the
effect of including these trials.
The mean treatment effects were then pooled to
get a weighted average of the study means using a
fixed-effects model for continuous outcomes.28,29
Confidence intervals (CI) with 95% significance were
obtained for the pooled study means. In order to
test for heterogeneity between studies, the chi-
squared was calculated for the assumption of
homogeneity.
In order to evaluate the response to beta2-
agonist given after active treatment or placebo,
the new baseline used was the FEV1 taken after
study drug but prior to beta-agonist. The net
treatment effect was estimated by calculating the
ratio of FEV1 measured after agonist to the new
baseline for both placebo and active treatment,
and then comparing the treatment-agonist re-
sponse to the placebo-agonist response.
Results for respiratory symptoms were measured
as a risk difference, by subtracting the fraction of
participants in the placebo group with symptoms
from the fraction of those in the treatment group
with symptoms. For cross-over trials each partici-
pant was counted only once, even if they received
more than one treatment. It was planned to pool
the risk differences for respiratory symptoms using
the fixed effects model for dichotomous outcomes.
However, as there were very few participants with
increased respiratory symptoms, Poisson statistics
was used, separately for treatment and placebo, in
order to derive a CI for the pooled risk difference.
A subgroup analysis was performed to evaluate
the response of patients with severe COPD, as
defined by a mean baseline FEV1, for the group, of
less than 1.4 l or less than 50% normal predicted
value. Another subgroup analysis evaluated the
treatment response of participants known to have
reversible airway obstruction, documented by an
increase in FEV1 of at least 15% to beta-agonist
stimulation. A third analysis evaluated the response
for those known to have comorbid cardiovascular
conditions such as hypertension or angina. Trials
without placebo controls were evaluated separately.
Results
Search results
The database search identified 200 potentially
relevant articles. After review of the articles and
bibliographies, 39 trials of beta-blockers in patients
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with COPD were found. Of these, 19 met inclusion
criteria: 11 gave information on single-dose stu-
dies,30–40 and 8 provided data on treatment of
longer duration.41–48 Inter-rater agreement for
study eligibility was 92%, and consensus was
reached on the remaining 3 trials. Two of the
single-dose trials did not provide baseline controls,
and the results of these trials were reported
separately.35,39 Cardioselective beta1-blockers in-
cluded in the studies were atenolol, metoprolol,
bisoprolol, practolol, celiprolol and acebutolol.
Trials were excluded for the following reasons: 8
trials evaluated nonselective beta-blockers only, 2
studies were not randomised, 4 were not blinded, 1
did not provide FEV1 data or placebo controls, and
4 were reviews of other trials.
Methodological quality of included studies
All of the studies evaluated were small cross-over
trials that included a wash-out period between
treatment groups, and some of the trials were
single-blind instead of double-blind. Two of the
trials did not have placebo controls, and 1 study
merely evaluated different doses of a single drug
compared to baseline controls. The results of these
trials are reported separately. In addition, many
trials did not provide individual study SDs for the
FEV1 treatment effect, and sensitivity analysis
were performed to evaluate the effect of including
these trials. The drop-out rate was 1.5% for single-
dose studies and 3.5% for those of longer duration.
Quantitative data synthesis
Single-dose treatment results
Eleven studies on single-dose treatment included
141 participants, 80% of whom were men. There
was an average of 12.8 patients per study, and the
drop-out rate was 1.5%. From the available
information the mean age of participants was
53.8 (711.1) years. These baseline characteristics
were the same for the placebo and treatment
groups because all of the trials were cross-over by
design. The baseline FEV1 measured in the treat-
ment group was 1.64 (70.63) l, and in the placebo
group was 1.66 (70.64) l.
Single doses of beta1-blockers were not associated
with a change in FEV1 compared to placebo (2.05%
[CI, 6.05 to 1.96, Fig. 1]). The results were similar
for those trials without placebo controls (2.14%
[CI, 7.32 to 3.04]). No participants had increased
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respiratory symptoms with beta1-blockers or with
placebo in any of the trials, with a risk difference
(RD) of 0.0 (CI, 0.03 to 0.03). There was no
significant change in the FEV1 treatment effect after
beta2-agonist was given (1.21% [CI, 10.97 to 8.56,
Fig. 2]).
Longer duration treatment results
Data from 8 studies involving 126 participants (20.4
patient-years) were evaluated for treatment ef-
fects of longer duration ranging from 2 days to 3
months, with a mean trial duration of 1.1 months.
There was an average of 15.8 participants in each
study (77% of whom were men), with a 3.5% drop-
out rate. The average baseline FEV1 in the
treatment group was 1.74 (70.76) l, and for the
placebo group was 1.73 (70.77) l.
In the continued treatment trials, beta1-blockers
as a group did not significantly differ from placebo
in terms of FEV1 response (2.55% [CI, 5.94 to
0.84, Fig. 1]), number of patients with symptoms
(RD 0.0 [CI, -0.04 to 0.04]), or response to beta2-
agonists (2.0% [CI, 13.77 to 9.77, Fig. 2]).
Interstudy variance
There was minimal interstudy variance in the
measurement of FEV1 for single-dose studies
(P ¼ 0:62) and for studies of longer duration
(P ¼ 0:4). No evidence of interstudy heterogeneity
was seen for respiratory symptoms, for single-dose
studies (P ¼ 1) or for those with longer duration
(P ¼ 0:98).
Subgroup analyses
To evaluate the effect of treatment in patients with
severe chronic airways obstruction, 6 trials that
demonstrated an average baseline FEV1 of o1.4 l
or o50% normal predicted values were analysed
separately.35,38,41,43,44,48 There was no significant
difference in FEV1 treatment effect for the single-
dose studies (2.4% [CI, 8.67 to 3.87]) or for
those with continued treatment (3.11% [CI, 8.62
to 2.41]), and no increase in symptoms was seen in
any of the trials.
Another subgroup analysis concerned patients
who had COPD with a reversible component as
demonstrated by an improvement in FEV1 of at
least 15% after beta2-agonists.30,33,34,40,42–44 When
these 7 trials were analysed separately, there
still was no significant change in FEV1 seen in
single-dose trials (1.8% [CI, 7.01 to 3.41]) or
those of longer duration (1.26% [CI, 5.78 to
3.25]), and no increase in symptoms were found in
any study.
In 8 of the trials, all participants had comorbid
cardiovascular conditions such as hypertension or
angina.30,31,34,36,40,46–48 When only these trials
were included in the analysis, there was no
significant FEV1 treatment effect seen for
single-dose studies (1.8% [CI, 7.01 to 3.41]) or
for those of longer duration (4.20% [CI, 9.32
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to 0.92]), and no respiratory symptoms were seen
in the treatment group in any of the studies.
Sensitivity analyses
A sensitivity analysis was performed to evaluate the
effect of including trials that did not provide study
SDs for the FEV1 treatment effect.35,38,43,44,46
Excluding trials that did not provide SD data did
not significantly effect the results for single-dose
trials (3.01% [CI, 7.12 to 1.09]), or for those of
longer duration (2.5% [CI, 5.38 to 10.38]).
Comment
This meta-analysis demonstrates that cardioselec-
tive beta-blockers in patients with COPD produced
no significant change in FEV1 or respiratory
symptoms compared to placebo, and did not affect
the FEV1 treatment response to beta2-agonists.
These findings were unchanged in subgroup ana-
lyses of patients with severe COPD or for those with
a reversible obstructive component. These findings
are supported by a recent meta-analysis that
demonstrated that cardioselective beta-blockers
given to patients with reversible airway disease did
not produce clinically significant adverse respira-
tory effects.25
This meta-analysis has several limitations, some
that are similar to those found with most meta-
analyses.49 The analysis only reports on published
literature and is therefore subject to publication
bias. However, funnel plots of effect size versus
standard error for the trials in this review showed
no evidence of bias. A few studies did not have
placebo controls, and many did not provide
standard deviations for FEV1 treatment effects.
However, sensitivity analyses were performed to
evaluate the effect of including these trials and the
results were found to be consistent throughout, due
to the homogeneous nature of the individual trials.
Most of the studies were small and 80% of the
participants were men. The participants were
relatively young (mean age 54 years) with moder-
ately reduced FEV1 (1.6 l). In addition, most of the
studies were of short duration. It is possible that a
longer study period may be required in order to
detect clinically important side-effects of beta-
blockers.
The current standard of care is to avoid the use
of beta-blockers in patients with reactive or
obstructive airway disease.6,19–23 This reluctance
to use beta-blockers is based on case reports
of acute bronchospasm in patients with reversi-
ble airway disease precipitated by high doses of
non-cardioselective beta-blockers.50–53 Only a
small fraction of patients with heart disease who
would benefit from beta-blockers are currently
given this treatment.54–57 A recent study showed
that COPD and asthma were the co-morbidities
most commonly associated with beta-blockers
being withheld in elderly patients after a myocar-
dial infarction.58
This meta-analysis indicates that the use of
cardioselective beta-blockers is safe in patients
who have COPD, even in a subgroup of patients with
concomitant angina, ischemic heart disease or
hypertension. These findings are consistent with
other studies that have shown that the use of beta-
blockers in patients with COPD and concomitant
cardiovascular disease is well tolerated.59–65 An-
other study on survivors of myocardial infarction
included 46,000 patients with asthma or COPD, and
showed a significant reduction in total mortality for
those treated with beta-blockers compared to
those who were not.15
The studies in this meta-analysis gave doses of
beta1-blockers ranging from therapeutic to supra-
therapeutic doses, those that are not generally
used for initiation of treatment. For example,
subjects were given single doses of metoprolol or
atenolol ranging from 50 to 200mg, without a
clinically apparent effect on respiratory function.
However, it would be reasonable in clinical practice
to start treatment with a low daily dose of a beta1-
blocker, such as 25mg of atenolol, and titrate the
dose up as needed.
Due to the proven mortality benefit of beta-
blockers in numerous conditions, many of the other
relative or absolute contraindications traditionally
listed for beta-blockers have been questioned and
disproved, including impaired left ventricular func-
tion, peripheral vascular disease, diabetes melli-
tus, depression, and advanced age.11,15,66–74 This
meta-analysis suggests that cardioselective beta-
blockers may be given to patients with COPD, even
in those with a reversible component or with severe
baseline obstruction.
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